Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
- Details
- Category: AstraZeneca
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer)
Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program
- Details
- Category: Pfizer
Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today announced that the companies have entered into a global license agreement for Theravance Biopharma's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.
Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan® (rituximab)
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.
Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
- Details
- Category: AstraZeneca
AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 to recommend Lynparza (olaparib) as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer), whose disease has not progressed following 1st-line platinum-based chemotherapy.
Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement.
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
- Details
- Category: AstraZeneca
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).
New set-up for IT at Bayer
- Details
- Category: Bayer
Bayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses.
More Pharma News ...
- Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
- Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
- Roche and Spark Therapeutics, Inc. announce extension of tender offer
- AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
- AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
- FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
- Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer